Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial

https://www.thelancet.com/journals/landia/article/PIIS2213-8587(24)00182-7/abstract?utm_campaign=update-landia&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_landia&_hsenc=p2ANqtz-9F5I9tyWP-_l-TNCeqlSsdzD-BjEJJ3MjtwppICT4T0k7c-YZh0nLulyLHcyx8HuDl7NPOgeVWk1-0f9abXm4RfwAVvg&_hsmi=322926207&utm_content=322874420&utm_source=hs_email